Matthew Wilson
Last active: 3/24/2020

  1. Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Saito S, Nakazawa Y, Sueki A, Matsuda K, Tanaka M, Yanagisawa R, Maeda Y, Sato Y, Okabe S, Inukai T, Sugita K, Wilson MH, Rooney CM, Koike K (2014) Cytotherapy 16(9): 1257-69
    › Primary publication · 25108652 (PubMed) · PMC4948190 (PubMed Central)
  2. Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. Nakazawa Y, Saha S, Galvan DL, Huye L, Rollins L, Rooney CM, Wilson MH (2013) J Immunother 36(1): 3-10
    › Primary publication · 23211626 (PubMed) · PMC3521868 (PubMed Central)
  3. An adaptable system for improving transposon-based gene expression in vivo via transient transgene repression. Doherty JE, Woodard LE, Bear AS, Foster AE, Wilson MH (2013) FASEB J 27(9): 3753-62
    › Primary publication · 23752206 (PubMed) · PMC3752539 (PubMed Central)
  4. piggyBac transposon system modification of primary human T cells. Saha S, Nakazawa Y, Huye LE, Doherty JE, Galvan DL, Rooney CM, Wilson MH (2012) J Vis Exp (69): e4235
    › Primary publication · 23149543 (PubMed) · PMC3514050 (PubMed Central)
  5. Hyperactive piggyBac gene transfer in human cells and in vivo. Doherty JE, Huye LE, Yusa K, Zhou L, Craig NL, Wilson MH (2012) Hum Gene Ther 23(3): 311-20
    › Primary publication · 21992617 (PubMed) · PMC3300075 (PubMed Central)
  6. Comparative analysis of the recently discovered hAT transposon TcBuster in human cells. Woodard LE, Li X, Malani N, Kaja A, Hice RH, Atkinson PW, Bushman FD, Craig NL, Wilson MH (2012) PLoS One 7(11): e42666
    › Primary publication · 23166581 (PubMed) · PMC3499496 (PubMed Central)
  7. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. Nakazawa Y, Huye LE, Salsman VS, Leen AM, Ahmed N, Rollins L, Dotti G, Gottschalk SM, Wilson MH, Rooney CM (2011) Mol Ther 19(12): 2133-43
    › Primary publication · 21772253 (PubMed) · PMC3242651 (PubMed Central)
  8. Manipulating piggyBac transposon chromosomal integration site selection in human cells. Kettlun C, Galvan DL, George AL, Kaja A, Wilson MH (2011) Mol Ther 19(9): 1636-44
    › Primary publication · 21730970 (PubMed) · PMC3182353 (PubMed Central)
  9. Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. Huye LE, Nakazawa Y, Patel MP, Yvon E, Sun J, Savoldo B, Wilson MH, Dotti G, Rooney CM (2011) Mol Ther 19(12): 2239-48
    › Primary publication · 21878902 (PubMed) · PMC3242659 (PubMed Central)
  10. Tamoxifen-inducible podocyte-specific iCre recombinase transgenic mouse provides a simple approach for modulation of podocytes in vivo. Wang J, Wang Y, Long J, Chang BH, Wilson MH, Overbeek P, Danesh FR (2010) Genesis 48(7): 446-51
    › Primary publication · 20641128 (PubMed) · PMC3014324 (PubMed Central)